For patients with a history of HER2+ metastatic breast cancer but without evidence of other extracranial systemic disease who present with oligometastatic brain disease amenable to local therapy, there is insufficient evidence to make a recommendation for a change in systemic therapy. The gene discussed is ERBB2; the disease is breast carcinoma.